Harbin Medical University
114
15
21
25
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
7.0%
8 terminated/withdrawn out of 114 trials
75.8%
-10.7% vs industry average
9%
10 trials in Phase 3/4
8%
2 of 25 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (114)
Non-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis(EROSION IV)
Role: lead
Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
Role: lead
Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy
Role: lead
The Impact of Comprehensive Post Hospital Management Based on DHI on Cardiac Function in Patients With HF
Role: lead
Application of Low-dose Muscle Relaxants in Bronchoscopic Interventional Procedures
Role: lead
Ischemic Stroke Nutrition Intervention Study
Role: lead
Flow Patterns and Stent Thrombosis
Role: collaborator
Time-Restricted Eating for Weight-Loss Maintenance
Role: lead
A Coronary Computed Tomography Angiography-guided Intervention for High Risk Cardiovascular Disease Population in Rural China
Role: lead
Community-Empowerment and Environmental Enrichment-based Co-management (CEEEC) Model and Mechanisms for Improving Health of Older Stroke Patients With Multimorbidity
Role: collaborator
Heart Voice: Starry Journey - A Digital ACT Intervention for ASD Caregivers
Role: lead
Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)
Role: lead
A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment
Role: lead
The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel
Role: lead
Single-cell Multi-omics Analyses of OCT-diagnosed Plaque Subtypes in Coronary Artery Disease (MOOP-CAD)
Role: lead
Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer
Role: lead
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer
Role: lead
Prospective, Multicenter, Self-controlled Clinical Trial to Validate Optical Ultrasonic Flow Ratio (OUFR)
Role: lead
Artificial Intelligence-assisted Diagnosis
Role: collaborator
Cardiovascular Risk Early Screening and Warning in Harbin : A Prospective Cohort Study
Role: lead